spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  genetic medicine 

 HSMN NewsFeed - 16 Jul 2026
Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Apr 2026
Lilly to Acquire Ajax Therapeutics to Advance Outcomes for Patients with Myelofibrosis and Polycythemia Vera
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2026
Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Mar 2026
Argo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2026
Lilly to Acquire Orna Therapeutics to Advance Cell Therapies
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Aug 2025
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jun 2025
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Regenerative Medicine Ophthalmology Venture Capital
 HSMN NewsFeed - 8 May 2025
Lilly Announces Transitions in Executive Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 Jan 2025
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2025
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
Regenerative Medicine Cardiology Personnel
 HSMN NewsFeed - 19 Dec 2024
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 26 Nov 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 9 Sep 2024
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jul 2024
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Jun 2024
Lilly announces departure of Anat Ashkenazi, chief financial officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2024
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Mar 2024
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 5 Jan 2024
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 4 Jan 2024
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 27 Dec 2023
Lilly Completes Acquisition of POINT Biopharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Sep 2023
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Aug 2023
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Aug 2023
Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2023
Lilly to Acquire Sigilon Therapeutics
Biopharmaceuticals Endocrinology Mergers & Acquisitions
 HSMN NewsFeed - 27 Jun 2023
SonoThera(TM) Expands Leadership Team Appointing Carolyne Zimmermann as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2023
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2023
Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 8 Jun 2023
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 24 Apr 2023
Lilly to Divest BAQSIMI to Amphastar
Biopharmaceuticals Endocrinology Mergers & Acquisitions
 HSMN NewsFeed - 1 Mar 2023
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Feb 2023
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Jan 2023
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2022
Alexion, AstraZeneca Rare Disease to Acquire LogicBio(R) Therapeutics to Accelerate Growth in Genomic Medicine
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Jun 2022
Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 May 2022
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
Regenerative Medicine Orthopaedic Venture Capital
 HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2022
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
Biopharmaceuticals
 HSMN NewsFeed - 23 Sep 2021
DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production
Devices Personnel
 HSMN NewsFeed - 13 Jul 2021
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 May 2021
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
Biopharmaceutical Personnel
 HSMN NewsFeed - 10 May 2021
LogicBio Therapeutics Strengthens Management Team with Key Appointments
Regenerative Medicine Personnel
 HSMN NewsFeed - 29 Apr 2021
Capsida Biotherapeutics Debuts with $140 Million of Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Aug 2020
BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Aug 2020
StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2020
Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Feb 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2020
enGene Announces Additions to Senior Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 31 May 2017
Homology Medicines Strengthens Manufacturing and Product Development Expertise with Appointment of Tim Kelly as Senior Vice President, Technical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jun 2016
Homology Medicines Appoints James Warren, Ph.D. as Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2016
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2015
Precision NanoSystems Raises $13.4M in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Aug 2015
WAVE Life Sciences Raises $66 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jun 2015
Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2014
Surgeons of the University Hospital Essen Complete World's First Robotic-Assisted Cancer Surgery with Medrobotics' Flex(R) System
Devices Oncology Surgery
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2014
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 13 Jan 2014
Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Oct 2013
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 26 Aug 2013
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 14 Oct 2009
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jun 2009
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2008
FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2008
Naglazyme Approved by Japanese Ministry of Health
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2007
Gerard McGarrity Joins VIRxSYS as Executive Vice President of Scientific and Clinical Affairs
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
genetic medicine
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!